IMJUDO

NDC 0310-4505 · AstraZeneca Pharmaceuticals LP

Generic nametremelimumab

Dosage formINJECTION, SOLUTION

RouteINTRAVENOUS

Active ingredient(s)TREMELIMUMAB

Strength25 mg/1.25mL

Pharmacologic classCTLA-4-directed Antibody Interactions [MoA], CTLA-4-directed Blocking Antibody [EPC], Increased T Lymphocyte Activation [PE]

Marketing categoryBLA

Packages

0310-4505-25 — 1 VIAL in 1 CARTON (0310-4505-25) / 1.25 mL in 1 VIAL

J9347 — Injection, tremelimumab-actl, 1 mg Medicare Part B payment limit (ASP + 6%): $146.89

FDA lists these products with the same active ingredient.

0310-4535 — tremelimumab

From the FDA National Drug Code Directory, retrieved 2026-08-24. Product listings are submitted by labelers; FDA does not verify them.